Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer
Navonil De Sarkar, … , Robert B. Montgomery, Peter S. Nelson
Navonil De Sarkar, … , Robert B. Montgomery, Peter S. Nelson
Published December 8, 2021
Citation Information: JCI Insight. 2021;6(23):e152789. https://doi.org/10.1172/jci.insight.152789.
View: Text | PDF
Research Article Oncology

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer

  • Text
  • PDF
Abstract

Cancers with homology-directed DNA repair (HRR) deficiency exhibit high response rates to poly(ADP-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy. Though mutations disrupting BRCA1 and BRCA2 associate with HRR deficiency (HRRd), patterns of genomic aberrations and mutation signatures may be more sensitive and specific indicators of compromised repair. Here, we evaluated whole-exome sequences from 418 metastatic prostate cancers (mPCs) and determined that one-fifth exhibited genomic characteristics of HRRd that included Catalogue Of Somatic Mutations In Cancer mutation signature 3. Notably, a substantial fraction of tumors with genomic features of HRRd lacked biallelic loss of a core HRR-associated gene, such as BRCA2. In this subset, HRRd associated with loss of chromodomain helicase DNA binding protein 1 but not with mutations in serine-protein kinase ATM, cyclin dependent kinase 12, or checkpoint kinase 2. HRRd genomic status was strongly correlated with responses to PARPi and platinum chemotherapy, a finding that supports evaluating biomarkers reflecting functional HRRd for treatment allocation.

Authors

Navonil De Sarkar, Sayan Dasgupta, Payel Chatterjee, Ilsa Coleman, Gavin Ha, Lisa S. Ang, Emily A. Kohlbrenner, Sander B. Frank, Talina A. Nunez, Stephen J. Salipante, Eva Corey, Colm Morrissey, Eliezer Van Allen, Michael T. Schweizer, Michael C. Haffner, Radhika Patel, Brian Hanratty, Jared M. Lucas, Ruth F. Dumpit, Colin C. Pritchard, Robert B. Montgomery, Peter S. Nelson

×

Full Text PDF | Download (11.32 MB)


Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts